Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Sanofi crawled date : 2021 - 08 - 30 save search
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
Published: 2021-08-30 (Crawled : 21:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -0.46%
LGND | $72.59 0.1% 0.1% 140K
|
Health Technology
|
| O: 0.65%
H: 5.84%
C: 5.28%
treatment china approval
JHL Co-founders Convicted of Trade Secret Theft
Published: 2021-08-30 (Crawled : 19:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -0.46%
Regeneron and Sanofi Monopoly on Atopic Dermatitis Market May Soon End
Published: 2021-08-30 (Crawled : 16:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -0.46%
dermatitis atopic dermatitis
Deebio's Global Bio-enzyme Journey: 27 Years, 30 Countries and Regions
Published: 2021-08-30 (Crawled : 13:15) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -0.46%
Convergent Therapeutics Appoints Alexander Brown as Chief Operating Officer
Published: 2021-08-30 (Crawled : 12:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -0.46%
therapeutics
The Impact of Price Intelligence in High Tech
Published: 2021-08-30 (Crawled : 10:00) - modeln.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -0.46%
Innate Pharma to Participate in Upcoming Investor Conferences - Aug 30, 2021
Published: 2021-08-30 (Crawled : 08:00) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.18%
H: 1.47%
C: 0.95%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -0.46%
IPHA | $2.48 5.53% 5.24% 9.4K
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: -0.28%
conference pharma
Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
Published: 2021-08-30 (Crawled : 05:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -0.46%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.63%
H: 2.21%
C: 1.97%
dermatitis children trial atopic dermatitis dupixent
Innate Pharma to Participate in Upcoming Investor Conferences
Published: 2021-08-30 (Crawled : 05:00) - globenewswire.com
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -1.18%
H: 1.47%
C: 0.95%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -0.46%
IPHA | $2.48 5.53% 5.24% 9.4K
|
Health Technology
|
| O: 1.42%
H: 0.0%
C: -0.28%
conference pharma
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.